UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

Breast cancer research : BCR, 2023-11, Vol.25 (1), p.138-138, Article 138

2023

Volltextzugriff (PDF)

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Breast cancer research : BCR, 2021-08, Vol.23 (1), p.1-11, Article 88

2021

Volltextzugriff (PDF)

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Clinical cancer research, 2011-04, Vol.17 (8), p.2400-2409

2011

Volltextzugriff (PDF)

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4449-4457

2008

Volltextzugriff (PDF)

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

EJNMMI research, 2024-03, Vol.14 (1), p.32-11, Article 32

2024

Volltextzugriff (PDF)

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

Clinical cancer research, 2013-04, Vol.19 (7), p.1884-1893

2013

Volltextzugriff (PDF)

Test–Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network

The Journal of nuclear medicine (1978), 2019-05, Vol.60 (5), p.608-614

2019

Volltextzugriff (PDF)

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Clinical cancer research, 2010-05, Vol.16 (10), p.2803-2810

2010

Volltextzugriff (PDF)

Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient

Clinical cancer research, 2009-09, Vol.15 (17), p.5294-5296

2009

Volltextzugriff (PDF)

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Journal of clinical oncology, 2014-12, Vol.32 (34), p.3840-3847

2014

Volltextzugriff (PDF)

Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Breast cancer research and treatment, 2007-09, Vol.105 (1), p.87-94

2007

Volltextzugriff (PDF)

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

The lancet oncology, 2024-04, Vol.25 (4), p.474-487

2024

Volltextzugriff (PDF)

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Clinical cancer research, 2016-06, Vol.22 (12), p.2855-2864

2016

Volltextzugriff (PDF)

Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016

Radiology, 2021-08, Vol.300 (2), p.204581-300

2021

Volltextzugriff (PDF)

Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status

Cancer, 2023-04, Vol.129 (8), p.1173-1182

2023

Volltextzugriff (PDF)

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.925-e1918

2021

Volltextzugriff (PDF)

Optimal duration of trastuzumab for early HER2-positive breast cancer

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1167-1168

2017

Volltextzugriff (PDF)

qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue

PloS one, 2024-06, Vol.19 (6), p.e0303057

2024

Volltextzugriff (PDF)

Advances in molecular imaging for breast cancer detection and characterization

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.206-206, Article 206

2012

Volltextzugriff (PDF)

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Clinical cancer research, 2011-07, Vol.17 (14), p.4799-4805

2011

Volltextzugriff (PDF)

Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

American journal of clinical oncology, 2023-12, Vol.46 (12), p.567-571

2023

Volltextzugriff (PDF)

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Molecular imaging and biology, 2014-06, Vol.16 (3), p.431-440

2014

Volltextzugriff (PDF)

18 F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer

Journal of Nuclear Medicine, 2021-02, Vol.62 (2), p.184-190

2021

Volltextzugriff (PDF)

18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

The Journal of nuclear medicine (1978), 2021-02, Vol.62 (2), p.184-190

2021

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(165)

Publikationsform

Artikel
(182)
Tagungsberichte
(1)

Sprache

Englisch
(182)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(77)
Humans
(62)
Female
(47)
Oncology
(41)
Breast Cancer
(31)
Middle Aged
(27)
Adult
(26)
Tumors
(22)
Aged
(20)
Breast Neoplasms - Pathology
(20)
Animals
(19)
Mice
(15)
Patients
(15)
Breast Neoplasms - Diagnostic Imaging
(14)
Microbiology
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Cancer
(13)
Biological And Medical Sciences
(12)
Biomarkers
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

Test–Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016

Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors

Optimal duration of trastuzumab for early HER2-positive breast cancer

qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue

Advances in molecular imaging for breast cancer detection and characterization

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

18 F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer

18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Suchergebnisse filtern